Physician profile
Marlene Whaley
NPI 1609205442
$2,045.16
in general payments reported to CMS, 2019-2025
31 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $625 · 2023: $144 · 2024: $508 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $218.25 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $194.64 | 2021-2024 | |
| Pfizer INC. | $164.36 | 2021-2024 | |
| Glaxosmithkline, LLC. | $120.88 | 2021-2025 | Shingrix, Arexvy |
| Amgen INC. | $115.02 | 2021-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $70.45 | 2021-2022 | |
| Corcept Therapeutics | $66.05 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $65.00 | 2021-2025 | Vaxneuvance, Vaxelis, Capvaxive |
| Abbott Laboratories | $60.61 | 2022-2023 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.01 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.31 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $46.70 | 2022 | |
| Amarin Pharma, INC. | $45.47 | 2021-2022 | |
| Esperion Therapeutics, INC. | $39.75 | 2021-2023 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $38.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $38.78 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $31.44 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $30.08 | 2021-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $29.94 | 2025 | The Cologuard Plus Collection Kit |
| Medtronic, INC. | $25.64 | 2024 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $23.45 | 2024 | |
| Ani Pharmaceuticals, INC. | $19.42 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $18.86 | 2024 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $16.26 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.56 | 2022 | |
| Daiichi Sankyo INC. | $14.60 | 2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $14.51 | 2021 | |
| Astellas Pharma US INC | $13.55 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $13.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Whaley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.